2 results
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Approved WMORecruiting
The primary objective of this study is to evaluate the safety and tolerability and determine the MTD and RDE(s) of INCB123667 as monotherapy in participants with selected advanced or metastatic solid tumors.The secondary objective is to evaluate theā¦